Evidence map›Paper›PMID 41930203›Full record

ArticleFrontiers in oncology2026

Successful conversion therapy of advanced gallbladder carcinoma by chemotherapy combined with immunotherapy: two case reports.

Long Li, Bing Tong, Wei Gong, Haisheng Xu, Xiaofeng Liao, Huapeng Sun

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Long LiSchool of Medicine, Wuhan University of Science and Technology, Wuhan, China.
Bing TongDepartment of General Surgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Wei GongDepartment of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Haisheng XuDepartment of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Xiaofeng LiaoDepartment of General Surgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Huapeng SunDepartment of General Surgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gallbladder cancer (GBC) is a highly aggressive malignancy of the biliary system and is frequently diagnosed at an advanced stage upon initial presentation. Nonetheless, the introduction of conversion therapy has allowed certain initially inoperable cases of GBC to become candidates for radical resection after comprehensive modalities, including chemotherapy, immunotherapy, and radiotherapy. In the current retrospective analysis, we present two patients with initially unresectable GBC treated at Xiangyang Central Hospital, affiliated with Hubei University of Arts and Science. After receiving a combination of chemotherapy and immunotherapy, substantial tumor regression was observed at both primary and metastatic sites, achieving partial remission according to the Response Evaluation Criteria in Solid Tumors (RECIST). Conversion therapy proved effective, enabling both patients to undergo successful radical resections. Following surgery, the original therapeutic regimen was continued until completion of five cycles. Follow-up extended through November 2025, with no evidence of tumor recurrence observed.

Indexed as

chemotherapyconversion therapygallbladder cancerimmunotherapy combined therapyradical operation

Identifiers

PMID41930203
PMCPMC13042201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.